Lv1
18 积分 2022-06-29 加入
Resmetirom for NASH: balancing promise and prudence
1个月前
已完结
Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH)
1个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1个月前
已完结
Resmetirom: First Approval
1个月前
已完结
A Transposon-Based Mouse Model of Hepatocellular Carcinoma via Hydrodynamic Tail Vein Injection
1个月前
已完结
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma
1个月前
已完结
DAMPs and DAMP-sensing receptors in inflammation and diseases
1个月前
已完结
Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation
1个月前
已完结
Function and regulation of ULK1: From physiology to pathology
1个月前
已完结
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy
2个月前
已完结
皖公网安备34019202002308
